Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

This document is an administrative notice recording the comment, notice, and finalization dates for MolDX: EndoPredict® Breast Cancer Gene Expression Test (LCD L37295). It does not specify clinical coverage indications, limitations, documentation requirements for claims, or frequency limits.

"MolDX: EndoPredict® Breast Cancer Gene Expression Test (LCD L37295) comment period was 06/01/2017–08/14/2017; notice period 12/14/2017–01/29/2018; LCD became final on 01/30/2018."

Sign up to see full coverage criteria, indications, and limitations.